Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective: This study evaluated patient and treatment (galantamine and other acetylcholinesterase inhibitors (AChEIs)) factors associated with the time until nursing home placement (NHP) in patients with Alzheimer's disease (AD) with and without cerebrovascular disease (CVD). Methods: Re‐contact follow‐up study conducted in 2004 of 548 patients who had previously participated in RCTs with galantamine. Time to NHP was analyzed using Kaplan‐Meier estimates and Cox regression analysed factors associated with NHP. Results: There were 57% of female subjects and the mean age (SE) was 73.6 (±0.33) years. Within this cohort 78% of patients had AD, and 22% had AD with CVD. Overall, 59% of subjects had a NHP (median 42.4 months 95%CI: 38.0–48.0). The Cox regression model identified higher baseline Disability Assessment in Dementia (DAD) and Mini Mental State Examination (MMSE) scores, diagnosis (AD with CVD vs AD), living with caregiver, country, and treatment duration with galantamine or other AChEIs as factors associated with a reduced risk of institutionalization (p < 0.05). For each year of treatment with galantamine or other AChEI, the risk of being admitted to a nursing home within a given period was reduced by 31% (galantamine) and 29% (other AChEI). Conclusions: Long‐term treatment with galantamine or other AChEIs appears to be associated with a significant delay in the time to NHP in patients with AD and AD with CVD. Further prospective studies are needed to confirm these findings. Copyright © 2008 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patient and Caregiver Characteristics and Nursing Home Placement in Patients With Dementia
Yaffe, K. (2002) · JAMA · doi:10.1001/jama.287.16.2090 · Cited by 903
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08267-3 · Cited by 752
Galantamine treatment of vascular dementia: A randomized trial
Auchus, A. P., Brashear, H. R., Salloway, S., Korczyn, A. D., De Deyn, P. P., & Gassmann-Mayer, C. (2007) · Neurology · doi:10.1212/01.wnl.0000266625.31615.f6 · Cited by 189
Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P., & Damaraju, C. V. (2004) · Archives of Neurology · doi:10.1001/archneur.61.2.252 · Cited by 167
Cited by
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Differential diagnosis of neurodegenerative diseases using structural MRI data
Koikkalainen, J., Rhodius-Meester, H., Tolonen, A., Barkhof, F., Tijms, B., Lemstra, A. W., Tong, T., Guerrero, R., Schuh, A., Ledig, C., et al. (2016) · NeuroImage: Clinical · doi:10.1016/j.nicl.2016.02.019 · Cited by 193
“First, it has been shown that early diagnosis combined with current treatments can delay hospitalization (Feldman et al., 2009), and the importance of the early diagnosis will dramatically increase as soon as disease-modifying drugs become available (Siemers et al.”
BackgroundEska, K., Graessel, E., Donath, C., Schwarzkopf, L., Lauterberg, J., & Holle, R. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000355079 · Cited by 119
Pre-Diagnosis Excess Acute Care Costs in Alzheimer’s Patients among a US Medicaid Population
Geldmacher, D. S., Kirson, N. Y., Birnbaum, H. G., Eapen, S., Kantor, E., Cummings, A. K., & Joish, V. N. (2013) · Applied Health Economics and Health Policy · doi:10.1007/s40258-013-0038-9 · Cited by 53
The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease
Cappell, J., Herrmann, N., Cornish, S., & Lanctôt, K. L. (2010) · CNS Drugs · doi:10.2165/11539530-000000000-00000 · Cited by 57
Metadata
- Authors
- Feldman, H. H., Pirttila, T., Dartigues, J. F., Everitt, B., Van Baelen, B., Schwalen, S., & Kavanagh, S.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2008-11-04
- Volume
- 24
- Issue
- 5
- Pages
- 479-488
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W2152064324
- Cited by
- 67
- References
- 5
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.